MX2019003058A - Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). - Google Patents

Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).

Info

Publication number
MX2019003058A
MX2019003058A MX2019003058A MX2019003058A MX2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A MX 2019003058 A MX2019003058 A MX 2019003058A
Authority
MX
Mexico
Prior art keywords
antibodies
monoclonal antibodies
programmed death
novel monoclonal
present
Prior art date
Application number
MX2019003058A
Other languages
English (en)
Inventor
Li Jing
Li Dong
Zheng Yong
Zhang Xinhua
Gololobov Gennady
Yang Baotian
Tang Zhewei
Xu Jianqing
Wang Zhuozhi
Original Assignee
Cstone Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals filed Critical Cstone Pharmaceuticals
Publication of MX2019003058A publication Critical patent/MX2019003058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales PD-1, particularmente anticuerpos monoclonales humanos de PD-1, que se unen específicamente a PD-1 con alta afinidad y comprenden una cadena pesada y una cadena ligera. La presente invención proporciona además una secuencia de ácido nucleico que codifica los anticuerpos de la invención, los vectores de clonación o expresión, las células hospederas y los métodos para expresar o aislar los anticuerpos. También se proporcionan inmunoconjugados, composiciones terapéuticas que comprenden los anticuerpos de la invención. La invención también proporciona métodos para tratar diversos cánceres con anticuerpos anti-PD-1.
MX2019003058A 2016-09-21 2016-09-21 Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). MX2019003058A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/099576 WO2018053709A1 (en) 2016-09-21 2016-09-21 The novel monoclonal antibodies to programmed death 1 (pd-1)

Publications (1)

Publication Number Publication Date
MX2019003058A true MX2019003058A (es) 2019-11-28

Family

ID=61690082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003058A MX2019003058A (es) 2016-09-21 2016-09-21 Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).

Country Status (11)

Country Link
US (3) US11414487B2 (es)
EP (1) EP3515938A4 (es)
JP (2) JP7101169B2 (es)
KR (2) KR102527160B1 (es)
AU (1) AU2016423559C1 (es)
BR (1) BR112019005316A2 (es)
CA (1) CA3037407C (es)
IL (1) IL265525A (es)
MX (1) MX2019003058A (es)
RU (1) RU2757316C2 (es)
WO (1) WO2018053709A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018002824A2 (pt) 2015-08-11 2018-11-06 Open Monoclonal Tech Inc anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
ES2898025T3 (es) 2016-11-02 2022-03-03 Jounce Therapeutics Inc Anticuerpos contra PD-1 y sus usos
BR112020002013B1 (pt) 2017-08-03 2023-01-24 Amgen Inc Muteínas de il-21, método de preparação das mesmas, ácido nucleico, vetor, célula hospedeira, kit, uso dos mesmos e composição farmacêutica
CA3087273A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
AU2019254215A1 (en) * 2018-04-15 2020-10-22 Salubris (Chengdu) Biotech Co., Ltd Antibodies binding PD-1 and uses thereof
KR20230110841A (ko) * 2018-04-15 2023-07-25 임비라 컴퍼니 리미티드 Pd-1에 결합하는 항체 및 그 용도
CN109160949B (zh) * 2018-07-23 2021-05-14 中国医学科学院血液病医院（血液学研究所） 一种鼠抗人pd-1单克隆抗体及应用
CN113727731B (zh) * 2019-04-26 2023-06-02 上海药明生物技术有限公司 靶向pd-1和lag-3的双特异性抗体
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
KR20220102609A (ko) 2019-09-25 2022-07-20 우시 바이올로직스 아일랜드 리미티드 신규한 항-pd-l1 항체
BR112022009042A2 (pt) * 2019-11-11 2022-10-11 Cstone Pharmaceuticals Suzhou Co Ltd Combinações farmacêuticas, composições farmacêuticas, kits e métodos para tratar um câncer
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业（苏州）有限公司 Cdk4/6抑制剂的组合疗法
WO2022068919A1 (zh) * 2020-09-30 2022-04-07 正大天晴康方(上海)生物医药科技有限公司 结合pd-1抗体的肽及其应用
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
BR112023015652A2 (pt) 2021-02-04 2023-10-17 Genuv Inc Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a um epítopo de uma proteína de morte celular programada 1 (pd-1); molécula de ácido nucleico; vetor de clonagem ou de expressão; célula hospedeira; método para produzir o anticorpo ou fragmento de ligação a antígeno do mesmo; animal transgênico; molécula de ligação a antígeno multiespecífico, imunoconjugado, receptor de antígeno quimérico, receptor de célula t modificado ou vírus oncolítico; composição farmacêutica para prevenir ou tratar uma afecção associada a pd-1; método para prevenir ou tratar tumores, doenças autoimunes de câncer, doenças autoimunes, doenças neurológicas, doenças neurodegenerativas ou doenças infecciosas; composição farmacêutica para aumentar uma resposta imunológica em um indivíduo que tem câncer; e hibridoma
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
CN116036266A (zh) * 2022-12-28 2023-05-02 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗结肠癌患者的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123413A1 (en) 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
PL2439273T3 (pl) * 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP6285414B2 (ja) * 2012-03-30 2018-02-28 モルフォテック， インコーポレイテッド Ｔｅｍ−１診断用抗体
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EA201791768A1 (ru) 2015-02-06 2018-07-31 КАДМОН КОРПОРЕЙШН, ЭлЭлСи Иммуномодулирующие агенты
BR112018002824A2 (pt) 2015-08-11 2018-11-06 Open Monoclonal Tech Inc anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
CA3000564A1 (en) 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
CN109575139A (zh) * 2017-09-29 2019-04-05 上海药明生物技术有限公司 针对表皮生长因子受体和程序性死亡受体的双特异抗体

Also Published As

Publication number Publication date
IL265525A (en) 2019-05-30
US20230014722A1 (en) 2023-01-19
WO2018053709A1 (en) 2018-03-29
US11414487B2 (en) 2022-08-16
AU2016423559B2 (en) 2020-07-30
CA3037407A1 (en) 2018-03-29
JP2019536432A (ja) 2019-12-19
KR102273634B1 (ko) 2021-07-07
US20240101676A1 (en) 2024-03-28
RU2019111277A (ru) 2020-10-23
JP7101169B2 (ja) 2022-07-14
AU2016423559C1 (en) 2020-11-19
KR102527160B1 (ko) 2023-04-28
AU2016423559A1 (en) 2019-04-04
BR112019005316A2 (pt) 2019-09-03
CA3037407C (en) 2022-10-18
KR20190072524A (ko) 2019-06-25
EP3515938A1 (en) 2019-07-31
JP2021120378A (ja) 2021-08-19
KR20210104749A (ko) 2021-08-25
EP3515938A4 (en) 2020-06-10
RU2757316C2 (ru) 2021-10-13
RU2019111277A3 (es) 2020-10-23
US20200002420A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2019003058A (es) Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).
MX2021011697A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX2017012429A (es) Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3).
MD4716C1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
NZ738008A (en) Tigit-binding agents and uses thereof
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
NZ738979A (en) Pd-1 antibodies
SG10201907161YA (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
WO2015142675A8 (en) Treatment of cancer using chimeric antigen receptor
EP4249066A3 (en) Antibodies to tigit
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
MX2015015037A (es) Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
PH12019500571A1 (en) Anti-pd-1 antibodies
PH12019502298A1 (en) Monoclonal antibody to pd-l1
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения